Company / Operating Cash Flow per Share
Mineralys Therapeutics, Inc. Operating Cash Flow per Share History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.43
FY2024
5-year range
-$5.65 / -$2.24
FY2022-FY2024
Trend
-52.8%
vs FY2023
Sector context
#176 of 212
Health Care
What the data says
Mineralys Therapeutics, Inc.'s operating cash flow per share of $-3.43 is lower than 83% of companies in the Health Care sector (FY2024). Improved from $-5.65 to $-3.43 over the past 2 years.
Based on SEC 10-K filings.
-3.43 in FY2024.
Improved from $-5.65 to $-3.43 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 212This company -$3.43 Sector average -$14.72
▼
+76.7% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share decreased 52.8% year-over-year.
- Ranks #176 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.43 | -52.8% |
| FY2023 | -$2.24 | +60.3% |
| FY2022 | -$5.65 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026